1st Edition





CANCER RESEARCH CENTER MARSEILLE





CONFIRMED SPEAKERS

Martin Bergö (Stockholm, Sweden)
René Bernards (Amsterdam. The Netherlands)

Raffaele Colombo (Vancouver, Canada) Nelson Dusetti (Marseille, France)

Patrick Mehlen (Lvon. France)

Gérard Milano (Nice, France)

Javad Nazarian (Zurich, Switzerland)

Angela Nieto (Alicante, Spain)

Thales Papagiannakopoulos (New York, USA)

Angela Riedel (Wurzburg, Germany)

Giorgio Seano (Paris, France)

Sophie Tartare-Deckert (Nice, France)

Alissa Weaver (Nashville, USA)

Mattia Zampieri (Basel, Switzerland)

ORGANIZING COMMITTEE

Joseph Ciccolini, Nelson Dusetti, Christophe Ginestier, Luca Lignitto, Emilie Mamessier, Eddy Pasquier, Sophie Vasseur

With the valuable support of the junior researchers:

Agathe Cohendet, Georgios Efthymiou, Julie Lafont, Raphael Leblanc, Shuheng Lin, Maëlle Picard, Celia Sequera-Hurtado, Romain Zakrajsek 4 - 6 February 2026

MARSEILLE

Palais du Pharo

TOPICS/SESSIONS

Innovative therapies

Tumor microenvironment & cellular cross-talk Challenging sites of tumorigenesis: junior scientist session

Cancer progression and treatments

















EDITO

Dear Congress members, Dear participants, Dear Colleagues,

Welcome to Marseille.

We have the pleasure and the honor to invite you to participate at the first edition of the CRCM Symposium (Centre de Recherche en Cancérologie de Marseille) that emerges with a biannual intention.

Since 2008, CRCM scientists including 450 people and 21 teams, has been developping programs of basic and clinical research, with the unchanging desire to transfer fundamental data to the clinic, the « benchside to bed » principle that constitutes the foundation of our institution to make significant breakthroughs and improve the therapeutic management of cancer patients.

The symposium is organized around the scientific topics represented by two departments of CRCM: Comet (Cell Communication and Microenvironment) and Translate-IT (Translational research and Innovative therapies).

During these two days and a half, we gathered an exceptional program with diverse and state of the art sessions with special focus on tumour microenvironment and cellular crosstalk, based on metabolic and extra-vesicular communication, nanotechnologies, tumor cell signaling and pharmacologic innovations.

The Palais du Pharo will constitute a privileged venue to host the invited national and international keynote and lecture speakers with outstanding expertise in the cancerology domain. We are convinced that the surroundings and striking views of the Mediterranean and the Old Port, will be an additional incentive to participate in this extraordinary opportunity to build up new collaborations and favour exchanges with researchers and speakers.

Note the date in your agendas, we are looking forward to host many of you for this first session and specially encourage young scientists to register.

The Scientific and Organizing Committee













Comet



PROGRAM

WEDNESDAY FEBRUARY 4

16:00-17:00 General introduction

17:00-18:00

Innovative approaches to combat cancer drug resistance.

Keynote

René BERNARDS (Amsterdam, The Netherlands) Netherlands Cancer Institute, Amsterdam

18:00-19:00

Kevnote

Exosomes in Cancer Aggressiveness. Alissa WEAVER (Nashville, USA) Vanderbilt University School of Medecine

THURSDAY FEBRUARY 5

09:00-09:10 Welcome words

09:10-10:30

SESSION 1: Innovative Therapies - New therapies

09.10

Antibody Drug Conjugates: Facts & Fiction. Raffaele COLOMBO (Vancouver, Canada)

Kevnote

Zvmeworks

10.00

Lecture

Old wine in a New Bottle: Protacs in Oncology. Gérard MILANO (Nice, France)

Centre Antoine Lacassagne, Nice, France

10:30-11:00

Coffee Break

11:00-13:00

SESSION 1: Innovative Therapies - Therapy resistance and tumor plasticity

11:00

Lecture

Targeting glioblastoma cell state transitions induced by chemoradiation or neurosurgery.

Giorgio SEANO (Paris, France) Institut Curie, Paris-Orsay

11:30

Lecture

Deciphering drug modes of action by high-throughput metabolic profiling.

Mattia ZAMPIERI (Basel, Switzerland)

University of Basel

Lecture

Exploring therapy resistance in pancreatic cancer through transcriptomic signatures.

Nelson DUSETTI (Marseille, France) CRCM Cancer research center, Marseille

12:00

12:30 Oral communications

13:00-14:30 | Lunch Break - Posters Session

14:30-15:55

SESSION 2: Tumor microenvironment and cellular cross-talk

14.30

Kevnote

Redox regulation of cancer metastasis. Martin BERGO (Stockholm, Sweden)



Karolinska Institutet





Comet



PROGRAM

THURSDAY FEBRUARY 5

15.20 Lecture

Metabolic Mechanisms of Lung Cancer Progression. Thales PAPAGIANNAKOPOULOS (New York, USA)

Langone University

15:55-16:25 Coffee Break

16:25-18:30

SESSION 2: Tumor microenvironment and cellular cross-talk



16:25

17:10 Lecture

Role of melanoma cell plasticity in extracellular matrix remodeling and therapy

Oral communications

resistance Sophie TARTARE-DECKERT (Nice, France) The Mediterranean Centre for Molecular Medicine (C3M)

17:45 Oral communications

19:30 Congress Dinner

FRIDAY FEBRUARY 6

09:00-10:40

SESSION 3: Challenging sites of tumorigenesis: junior scientist session

09:00

Keynote

Understanding the biology of childhood high-grade gliomas:



from knowledge gaps to therapeutic opportunities. Javad NAZARIAN (Zurich, Switzerland)

University of Zürich

University Children's Hospital

10:00

Oral communications

10:40-11:00

Coffee Break

11:00-12:30

SESSION 3: Challenging sites of tumorigenesis: junior scientist session



11.00

Lecture

Understanding the link between immune evasion and metastasis:

A story of stromal - immune cell interactions in tumor-draining lymph nodes

Angela RIEDEL (Wurzburg, Germany), Greta MATTAVELLI (Germany) University of Würzburg

11:35 Oral communications

12:30-14:00 14:00-16:00

Lunch Break & Poster Sessions

14:00

SESSION 4: Cancer progression and treatments

Keynote



Cancer cell plasticity trajectories in the primary tumor and to the metastatic site. Angela NIETO (Alicante, Spain)

Instituto de Neurociencias (CSIC-UMH)

14:35

Targeting netrin-1 in oncology: from a cell biology hypothesis to clinical data.



Patrick MELHEN (Lyon, France) Research Cancer Center of Lyon (CRCL)

15:05 Oral communications

15:30 Poster / Talk prizes

15:45 Closing words





